Results 241 to 250 of about 465,548 (350)

Peripheral T-Cell Lymphoma Mimicking Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids: A Case Report with Confirmatory Brain Biopsy and Longitudinally Extensive Transverse Myelitis. [PDF]

Case Rep Neurol
Shen X, Su N, Zhang L, Zhang Y, Zhao D, Chen Q, Qian H, Yin H, Zhu Y.   +8 more
europepmc   +1 more source

Bruton tyrosine kinase (Btk) in neutrophils is indispensable for initiating and maintaining skin inflammation in a model of pemphigoid diseases

British Journal of Pharmacology, EarlyView.
Background and Purpose Bruton tyrosine kinase (Btk) is essential for B cell function. Its role in myeloid cells is less understood. Greater insights into Btk significance in myeloid cells are needed to evaluate its potential as a therapeutic target during the effector phase of antibody‐induced autoimmune diseases, where inhibiting autoantibody ...
Henning Olbrich, Paul Schilf, Sripriya Murthy, Sina Gonther, Mareike Neumann, Christoph M. Hammers, Jasper N. Pruessmann, Christian D. Sadik   +7 more
wiley   +1 more source

Epigenetic dysregulation of B‑cells in autoimmune diseases and lymphomas (Review). [PDF]

Int J Mol Med
Li Y, Gong Y, Zhao J, Ran R.
europepmc   +1 more source

Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

Journal of Clinical Oncology, 2014
M. Ogura, T. Ishida, K. Hatake, M. Taniwaki, K. Ando, K. Tobinai, K. Fujimoto, Kazuhito Yamamoto, T. Miyamoto, N. Uike, M. Tanimoto, K. Tsukasaki, K. Ishizawa, J. Suzumiya, H. Inagaki, K. Tamura, S. Akinaga, M. Tomonaga, R. Ueda   +18 more
semanticscholar   +1 more source

Combinatorial targeting of MYC/BCL2‐associated vulnerabilities in high‐grade B‐cell lymphoma

British Journal of Haematology, EarlyView.
Giulio Donati, Paola Nicoli, Federica Miele, Paola Podini, Giorgia Dina, Angelo Quattrini, Bruno Amati   +6 more
wiley   +1 more source

Impact of Achieving Progression‐Free Survival 24 on Subsequent Overall Survival in Diffuse Large B‐Cell Lymphoma Patients

Cancer Science, EarlyView.
The OS for patients after achieving PFS24 or PFS60 was not markedly different from that of the age‐, sex‐, and calendar period‐matched Japanese general population (PFS24: standardized mortality ratio [SMR] 1.29, 95% confidence interval [CI] 0.72–2.12, p = 0.39; PFS60: SMR 1.43, 95% CI 0.47–3.33, p = 0.55).
Ayumi Fujimoto, Wataru Munakata, Gakuto Ogawa, Ryunosuke Machida, Tomotaka Suzuki, Kazuyuki Shimada, Tsutomu Kobayashi, Ken Ohmachi, Tomohiro Kinoshita, Kiyoshi Ando, Dai Maruyama, Hirokazu Nagai   +11 more
wiley   +1 more source

Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.

Blood, 2014
F. Ellin, Jenny Landström, M. Jerkeman, T. Relander   +3 more
semanticscholar   +1 more source

Validation of prognostic scores in patients with HIV‐related diffuse large B‐cell lymphoma: The value of peripheral blood parameters—A study from the Spanish Lymphoma Group GELTAMO

British Journal of Haematology, EarlyView.
Maria Huguet, Mireia Morgades, Alfredo Rivas‐Delgado, Mariana Bastos‐Oreiro, Raúl Córdoba, Antonio Salar, Fátima de la Cruz‐Vicente, Miguel Alcoceba, Blanca Ferrer‐Lores, Ana Jiménez‐Ubieto, Antonio Gutiérrez, María Infante, Sofía Huerga, Pau Abrisqueta, David Cruz, Carlos Montalbán, Ana Muntañola, Sonia González‐de Villambrosia, Josep‐Maria Ribera, José‐Tomás Navarro   +19 more
wiley   +1 more source

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan

Cancer Science, EarlyView.
The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada, Akiko M. Saito, Kei Fukuhara, Masahiro Sekimizu   +12 more
wiley   +1 more source

Apheresis CD8⁺CCR7⁺CD45RA^- T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome. [PDF]

Int J Mol Sci
García de la Torre I, García-Hoz C, Martin-Moro F, Fernández-Velasco JI, Velázquez-Kennedy K, Rodríguez-Martín E, Luna De Abia A, Roldán E, Moreno Jiménez G, López-Jiménez J, Villar LM, Pariente-Rodríguez R.   +11 more
europepmc   +1 more source